Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: Comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies

Current Urology Reports

Volumn 5, Issue 6, 2004, Pages 467-471

  Padma Nathan, Harin ^a   McCullough, Andrew ^b   Forest, Christopher ^b  

^a The Male Clinic   (United States)

^b NONE

Author keywords

Erectile Dysfunction; Erectile Function; Radical Prostatectomy; Tadalafil; Vardenafil

Indexed keywords

CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; SILDENAFIL;

HUMAN; IMPOTENCE; MALE; METABOLISM; PROSTATECTOMY; REVIEW;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PROSTATECTOMY;

EID: 16644379053     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-004-0072-0     Document Type: Article

References (38)

1. Padma-Nathan H, McCullough A, Guiliano F, et al.: Postoperative nightly administration of sildenafil citrate significantly improves normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy. J Urol 2003, 169:375. This is the only placebo-controlled, randomized primary prevention study in the field of post-RRP-related erectile dysfunction. DOI: 10.1016/S0022-5347(03)80074-5
2. Fraiman M, Lepor H, McCullough A: Nocturnal penile tumescence activity in 81 patients presenting with erectile dysfunction after nerve sparing radical prostatectomy. J Urol 1991, 161:179.
3. McCullough A, Levine L, Padma-Nathan H: A prospective study of preoperative and postoperative nocturnal penile tumescence (NPT) in men undergoing bilateral nerve sparing radical prostatectomy (BNSRRP). J Androl 2002, 59:S134.
4. Fraiman MC, Lepor H, McCullough AR: Changes in penile morphometrics in men with erectile dysfunction after nervesparing radical retropubic prostatectomy. Mol Urol 1999, 3:109–115.
5. Klein LT, Miller MI, Buttyan R, et al.: Apoptosis in the rat penis after penile denervation. J Urol 1997, 158:626–630. DOI: 10.1016/S0022-5347(01)64572-5
6. User HM, Hairston JH, Zelner DJ, et al.: Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 2003, 169:1175–1179. DOI: 10.1097/01.ju.0000048974.47461.50
7. McCullough A, Ip C, Lepor H: The effect of preoperative potency on return of erectile function and Viagra response after radical retropubic prostatectomy RRP. Int J Impot Res 2001, 13:S68.
8. McCullough A, Ip C, Lepor H: The effect of age at the time of surgery on potency after nerve-sparing radical prostatectomy. Int J Impot Res 2001, 13:S68.
9. McCullough A, Woo K, Telegrafi S, Lepor H: Is sildenafil failure in men after radical retropubic prostatectomy (RRP) due to arterial disease? Penile duplex doppler findings in 174 men after RRP. Int J Impot Res 2002, 14:462–465. DOI: 10.1038/sj.ijir.3900909
10. Walsh PC: Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. J Urol 2000, 164:242.
11. Hong EK, Lepor H, McCullough AR: Time-dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot Res 1999, 11(suppl 1):S15-S22. DOI: 10.1038/sj.ijir.3900466
12. Partin AW, Kattan MW, Subong EN, et al.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997, 277:1445–1451. DOI: 10.1001/jama.277.18.1445
13. Blute ML, Bergstralh EJ, Partin AW, et al.: Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000, 164:1591–1595. DOI: 10.1016/S0022-5347(05)67035-8
14. Zippe CD, Jhaveri FM, Klein EA, et al.: Role of Viagra after radical prostatectomy. Urology 2000, 55:241–245. DOI: 10.1016/S0090-4295(99)00441-0
15. Raina R, Lakin MM, Agarwal A, et al.: Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 2003, 62:110–115. DOI: 10.1016/S0090-4295(03)00157-2
16. Brock G, Nehra A, Lipshultz LI, et al.: Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003, 170:1278–1283. DOI: 10.1097/01.ju.0000086947.00547.49
17. Montorsi F, Padma-Nathan H, McCullough A, et al.: Tadalafil in the treatment of erectile dysfunction following bilateral nervesparing radical retropubic prostatectomy: a randomized, double-blind, placebo-controlled study. J Urol 2004, in press.
18. Padma-Nathan H, Eardley I, Kloner R, et al.: A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002, 60(suppl 2B):67–90. DOI: 10.1016/S0090-4295(02)01752-1
19. European Agency for the Evaluation of Medicinal Products (EMEA): Committee for Proprietary Medicinal Products European Public Assessment Report: Cialis—International Non-Proprietary Name: tadalafil (CPMP/3960/02). London: European Agency for the Evaluation of Medicinal Products; 2002.http://www.emea.eu.int/humandocs/Humans/EPAR/cialis/ cialis.htm. Accessed October 21, 2004.
20. European Agency for the Evaluation of Medicinal Products (EMEA): Committee for Proprietary Medicinal Products European Public Assessment Report: Levitra—International Non-Proprietary Name: vardenafil (CPMP/6210/02). London: European Agency for the Evaluation of Medicinal Products; 2003. http:// www.emea.eu.int/humandocs/Humans/EPAR/levitra/levitra. htm. Accessed October 21, 2004.
21. Tadalafil USPI Labeling, US Food and Drug Administration, 2003.
22. Bischoff E, Niewohner U, Haning H, et al.: The inhibitory selectivity of vardenafil on bovine and human recombinant phosphodiesterase isoenzymes [Poster 113]. Int J Impot Res 2001, 13(suppl l4):41.
23. Laties A, Zrenner E: Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 2002, 21:485–506. DOI: 10.1016/S1350-9462(02)00013-7
24. Fawcett L, Baxendale R, Stacey P, et al.: Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A 2000, 97:3702–3707. DOI: 10.1073/pnas.050585197
25. Oliver JJ, Bell K, Leckie SM, et al.: Interaction between glyceryl trinitrate and sildenafil citrate may last less than 4 hours. Presented at the International Society for Sexual and Impotence Research. Montreal: September 26, 2002.
26. Kloner RA, Hutter AM, Emmick JT, et al.: Time course of the interaction between tadalafil and nitrates. J Am Col Cardiol 2003, 92:37M-46M.
27. Padma-Nathan H, Stecher V, Sweeney M, et al.: Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003, 62:400–403. DOI: 10.1016/S0090-4295(03)00567-3
28. Patterson B, Bedding A, Jewell H, et al.: The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 2001, 13(suppl 5):S63.
29. Porst H, Padma-Nathan H, Giuliano F, et al.: Efficacy of tadalafil in the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized clinical trial. J Urol 2004, in press.
30. Nichols DJ, Muirhead GJ, Harness JA: Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects, and dose proportionality. Br J Clin Pharmacol 2002, 53(supp 1):5S-12S. DOI: 10.1046/j.0306-5251.2001.00027.x
31. Muirhead GJ, Rance DJ, Walker DK, et al.: Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate. Br J Clin Pharmacol 2002, 53(suppl 1):13S-20S. DOI: 10.1046/j.06-5251.2001.00028.x
32. Rajagopalan P, Mazzu A, Xia C, et al.: The effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003, 43:1–8.
33. Vardenafil USPI labeling. US Food and Drug Administration, 2003.
34. Hellstrom WJ, Gittleman M, Karlin G, et al.: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002, 23:763–771.
35. Brock G, Nehra A, Lipshultz LI, et al.: Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003, 170:1278–1283. DOI: 10.1097/01.ju.0000086947.00547.49
36. Brock GB, McMahon CG, Chen T, et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of an integrated analysis. J Urol 2002, 168:1332–1336. DOI: 10.1016/S0022-5347(05)64442-4
37. Cialis Summary Basis for Approval: US Food and Drug Administration. http://www.fda.gov/cder/foi/nda/2003/21-368_Cialis.htm This presents the data in brief on the comparative head-to-head studies between sildenafil and tadalafil.
38. IMS Health Independent Prescription Data: April 9, 2004.